Sygnature Discovery, a leading provider of integrated drug discovery services, and Proteros, the most experienced and largest biotechnology company in the field of X-ray protein structure analysis, today announced they have entered into a strategic alliance.  

Under the terms of the agreement, Sygnature and Proteros will collaborate to provide integrated services to advance clients’ drug discovery projects.  This new alliance adds an integral component to Sygnature’s ‘federated’ CRO Model, which provides fully-integrated drug discovery services to the pharmaceutical industry.
 
Dr Torsten Neuefeind, CEO, Co-founder at Proteros said, "Sygnature has a growing reputation as a provider of premium integrated drug discovery services.  Proteros has worked with Sygnature on a number of drug discovery projects, so we already have an established working relationship.  This strategic alliance combines the complementary skills of Proteros and Sygnature Discovery.  Proteros will continue to provide X-ray protein structure analysis independently, but will also be able to contribute to fully-integrated drug discovery programmes via Sygnature’s ‘federated’ CRO model.  Working closely together on drug discovery projects, we are confident that Proteros and Sygnature can advance clients’ programmes more efficiently and effectively.”
 
Commenting on the strategic alliance, Dr Simon Hirst, Sygnature’s CEO said, “Proteros has specialist skills in early stage drug discovery that are highly-complementary to our own.  Proteros has an outstanding reputation for providing unique and best-in-class technologies for X-ray protein crystallography, kinetic and thermodynamic profiling and tailor-made protein production.  Sygnature and Proteros have already collaborated on a number of challenging client projects.  The close working relationship that we have established will be cemented through this strategic alliance.  With the addition of Proteros to the ‘federated’ CRO Model, it enables Sygnature to offer its customers a world class, fully-integrated drug discovery service where novel compounds can be designed, synthesised and screened in vitro at Sygnature, X-ray protein structure analysis undertaken at Proteros, metabolic liability and toxicity assessed at Cyprotex and then tested at Saretius and Pneumolabs in pharmocodynamic and disease-relevant models.  This powerful federation of alliance partners will help accelerate our clients’ drug discovery programmes towards development.”
 
About Sygnature Discovery Ltd.
Sygnature Discovery, founded in 2004 in Nottingham, UK, is a leading provider of integrated drug discovery services to pharmaceutical companies, biotechs and academics located in Europe and the USA.  Through its unique ‘federated’ CRO model, Sygnature undertakes complete drug discovery programmes and hit finding, hit-to-lead and lead optimisation projects for its clients.  The company employs over 70 laboratory-based, industry-experienced PhD medicinal chemists, computational chemists and in vitro biologists.  Sygnature has strategic alliances with Proteros (X-ray protein structure analysis), Cyprotex Discovery (ADME/toxicology), Saretius (pre-clinical pain/CNS and metabolic disease models), Pneumolabs (pre-clinical respiratory models), Horizon Discovery (X-Man^TM isogenic cell lines), and ChanTest (ion channel experts) to facilitate the delivery of top quality drug discovery services to its clients. 

more about Sygnature

more about Integrated Drug Discovery

About Proteros Biostructures GmbH
Proteros Biostructures, located in Martinsried/Munich, is a privately-held company, which provides a leading platform to support protein-structure accelerated drug discovery.  Proteros has established unique and best-in-class technologies for protein crystallography, kinetic and thermodynamic profiling and tailor-made protein production.  The service business consists of X-ray protein crystallography (expanding catalogue of Gallery Structure targets ready-to-use for structure analysis to gene-to-structure projects for the analysis of challenging targets), kinetic/thermodynamic compound profiling (generation of information allowing the discovery of drugs with desired residence time, kinetic selectivity and thermodynamic profile) and custom protein supply.  In response to customer requests, Proteros integrates these services with medicinal chemistry and a fragment library of novel target directed molecules to offer integrated lead discovery projects.  Proteros provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia.

more about Proteros